ArticleAntimicrobial agents and chemotherapy2013
Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02684240 (A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.Antimicrobial agents and chemotherapy · 2020Trial
- Potential Repurposed Drug Candidates for Tuberculosis Treatment: Progress and Update of Drugs Identified in Over a Decade.ACS omega · 2023Review
- Anti-Tuberculosis Activity of Three Carbapenems, Clofazimine and Nitazoxanide Using a Novel Ex Vivo Phenotypic Drug Susceptibility Model of Human Tuberculosis.Antibiotics (Basel, Switzerland) · 2022Article
- Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.Microorganisms · 2021Review
- Gastrointestinal microbiota composition predicts peripheral inflammatory state during treatment of human tuberculosis.Nature communications · 2021Article
- Protein Kinase R in Bacterial Infections: Friend or Foe?Frontiers in immunology · 2021Review
- Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action inFrontiers in cellular and infection microbiology · 2020Review
- Cytoplasmic RNA Sensor Pathways and Nitazoxanide Broadly Inhibit Intracellular Mycobacterium tuberculosis Growth.iScience · 2019Article
- The present state of the tuberculosis drug development pipeline.Current opinion in pharmacology · 2018Review
- Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs.ACS infectious diseases · 2018Article
- Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis.Frontiers in microbiology · 2018Review
- Rifamycin action on RNA polymerase in antibiotic-tolerantProceedings of the National Academy of Sciences of the United States of America · 2017Article
- Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.The Journal of antimicrobial chemotherapy · 2017Article
- Nitazoxanide is active against Mycobacterium leprae.PloS one · 2017Article
- Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.Tuberculosis (Edinburgh, Scotland) · 2016Article
- Antiinfectives targeting enzymes and the proton motive force.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2015Article
- New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.Immunological reviews · 2015Review
- Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Nitazoxanide (NTZ) has bactericidal activity against the H37Rv laboratory strain of Mycobacterium tuberculosis with a MIC of 16 μg/ml. However, its efficacy against clinical isolates of M. tuberculosis has not been determined. We found that NTZ's MIC against 50 clinical isolates ranged from 12 to 28 μg/ml with a median of 16 μg/ml and was unaffected by resistance to first- or second-line antituberculosis drugs or a diversity of spoligotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.